Safety and tolerability of donepezil at doses up to 20 mg/day: Results from a pilot study in patients with Alzheimer's disease

Drugs and Aging

Volumn 25, Issue 2, 2008, Pages 163-174

  Doody, Rachelle S ^a   Corey Bloom, Jody ^b   Zhang, Richard ^c   Li, Honglan ^d   Ieni, John ^d   Schindler, Rachel ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d EISAI INC   (United States)

Author keywords

Alzheime's disease, treatment; Donepezil, therapeutic use; Elderly

Indexed keywords

DONEPEZIL; PLACEBO;

ACCIDENTAL INJURY; ADULT; AGED; ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; BRADYCARDIA; CAREGIVER; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYNDROME; FECES INCONTINENCE; FEMALE; GAIT DISORDER; GLUCOSURIA; HEADACHE; HEMATOLOGIC DISEASE; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LABORATORY TEST; LIBIDO; LIPOMA; LOOSE FECES; MALE; MINI MENTAL STATE EXAMINATION; MYALGIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TINNITUS; TOOTH DISEASE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 38949095446     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825020-00008     Document Type: Article

References (29)

1. Pfizer Inc. Aricept [package insert]. New York: Pfizer Inc., 2005
2. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May 11; 158 (9): 1021-31
3. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology 1998 Jan; 50 (1): 136-45
4. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999 May-Jun; 10 (3): 237-44
5. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14; 57 (3): 489-95
6. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004 Jul; 19 (7): 624-33
7. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology 2001 Nov 27; 57 (10): 1942]. Neurology 2001 Aug 14; 57 (3): 481-8
8. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002 Dec; 14 (4): 389-404
9. Cummings JL, McRae T, Zhang R, et al. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006 Jul; 14 (7): 605-12
10. Hager K, Calabrese P, Frolich L, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15 (4): 189-98
11. Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16 (1): 15-24
12. Boada-Rovira M, Brodaty H, Cras P, et al. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21 (1): 43-53
13. Pratt RD, Perdomo CA, Surick IW, et al. Donepezil: tolerability and safety in Alzheimer's disease. Int J Clin Pract 2002 Nov; 56 (9): 710-7
14. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996 Nov-Dec; 7 (6): 293-303
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
16. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 Jul; 34 (7): 939-44
17. Matthews HP, Korbey J, Wilkinson DG, et al. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000 Aug; 15 (8): 713-20
18. Birks J. Cholinesterase inhibitors for Alzheimer's disease [online]. Available from URL: http://www.mrw.interscience.wiley.com/cochrane/clsysrev/ articles/CD005593/pdf_fs.html [Accessed 2007 Jan 9]
19. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000 Jan; 57 (1): 94-9
20. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998 Oct; 46 (10): 1223-7
21. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001 Dec 11; 57 (11): 2153]. Neurology 2001 Aug 28; 57 (4): 613-20
22. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001 Dec; 49 (12): 1590-9
23. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003 Aug 26; 61 (4): 479-86
24. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003 Oct; 34 (10): 2323-30
25. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998 Nov; 46 (1 Suppl.): 56S-60S
26. VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. Drugs Aging 2000 Feb; 16 (2): 123-38
27. Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002 Aug; 22 (8): 1001-6
28. Nagy CF, Kumar D, Perdomo CA, et al. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 2004 Nov; 58 (1 Suppl.): 25S-33S
29. Ritchie CW, Ames D, Clayton T, et al. Meta-analysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004 Jul-Aug; 12 (4): 358-69